Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label cannabidiol oral solution adjunctive study in Japanese patients with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex
jRCT2031220041Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cannabidiol in Lennox-Gastaut syndrome (LGS), Dravet syndrome and tuberous sclerosis complex (TSC), sponsored by Jazz Pharmaceuticals plc. Started Oct 2022; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
Lennox-Gastaut syndrome (LGS)Dravet syndrometuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on jRCT2031220041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220041.